Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Tilavonemab (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Sponsors AbbVie
- 02 Dec 2019 Status changed from active, no longer recruiting to completed.
- 07 Dec 2018 Planned End Date changed from 19 Oct 2020 to 13 Nov 2020.
- 23 Jul 2018 Status changed from recruiting to active, no longer recruiting.